Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project
Key result
A second TAVR for degenerated transcatheter aortic valves achieved a 79% VARC-2 device success rate, with 1-month and 1-year mortality rates of 2.9% and 10%, respectively.
Why the study?
Bioprosthetic valve durability remains a concern after TAVR, and little is known about managing degenerated transcatheter aortic valves with a second TAVR procedure.
Does a second TAVR safely and successfully treat patients with degenerated transcatheter aortic valves?
Population
172 patients with a degenerated TAV across 28 centers
Comparison
Second TAVR for stenotic vs regurgitant vs combined degenerated TAV
Design
International registry
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Registry data support redo TAVR feasibility in selected degenerated TAV; leaves open durability, selection criteria, and need for prospective confirmation.
Study Design
Type
Observational (n=172)
Multicenter
Yes
Structured PICO
Does a second TAVR safely and successfully treat patients with degenerated transcatheter aortic valves?
P
Population
172 patients with a degenerated transcatheter aortic valve treated with a second TAVR across 28 centers, followed for 1 year.
E
Exposure
Second transcatheter aortic valve replacement (TAVR)
O
Outcome
Valve Academic Research Consortium 2 (VARC-2) device success ratecomposite
A second TAVR is a safe and feasible treatment option for patients with degenerated transcatheter aortic valves, achieving a 79% device success rate and low 1-year mortality.
Cite This Study
Testa et al. (2021) conducted an observational in Degenerated transcatheter aortic valves (n=172). Second transcatheter aortic valve replacement (TAVR) was evaluated on Valve Academic Research Consortium 2 device success rate. A second TAVR for degenerated transcatheter aortic valves achieved a 79% VARC-2 device success rate, with 1-month and 1-year mortality rates of 2.9% and 10%, respectively.